fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Etidronate disodium

1 Limited Use · 1 not a benefit

Co Etidronate · DIN 02248686 · 200 mg · tablet

Limited Use, Reason for Use code 236, 237 required; Health Canada lists this DIN as Cancelled post market since 2022-05-30 — choose a marketed DIN from the same-category list.Discontinued May 30, 2022 · checked October 5, 2026
StatusLimited Use, Reason for Use code 236, 237 required; Health Canada lists this DIN as Cancelled post market since 2022-05-30 — choose a marketed DIN from the same-category list.
Write on scriptone applicable Reason for Use code, 236 or 237 (criteria below); Health Canada lists this DIN as Cancelled post market since 2022-05-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 236, 237
Reason for Use code 236 For the treatment of Paget's disease; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 237 For the management of hypercalcemia of malignancy. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Co Etidronate · DIN 02248686 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2005-01-25 Health Canada: Cancelled post market since 2022-05-30 · brand ACT ETIDRONATE · ATC M05BA01 ETIDRONIC ACID · form Tablet · route Oral · ingredients ETIDRONATE DISODIUM 200 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Co Etidronate: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3569). What the ministry pays, not the patient.

Ministry pays: $0.3569 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248686)

Source record
DIN 02248686: Co Etidronate Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000045; group id 912; item number 2186; lccId 00126; manufacturer id COB Source form: Tab; strength: 200mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3569; ministry $0.3569 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248686 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73050
Interchangeable products
Didronel · DIN 01997629 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248686
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 30, 2022 — choose a marketed DIN from the same-category list.

Didronel · DIN 01997629 · 200 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.Discontinued July 7, 2010 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 236, 237
Reason for Use code 236 For the treatment of Paget's disease; Coverage limit: LU Authorization Period: Indefinite Reason for Use code 237 For the management of hypercalcemia of malignancy. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Didronel · DIN 01997629 Manufacturer: Proctor & Gamble Pharmaceuticals Canada, Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2010-07-07 · brand DIDRONEL TAB 200MG · ATC M05BA01 ETIDRONIC ACID · form Tablet · route Oral · ingredients ETIDRONATE DISODIUM 200 MG · company Procter & gamble pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Didronel: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01997629)

Source record
DIN 01997629: Didronel Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000045; group id 912; item number 2186; lccId 00126; manufacturer id PGP Source form: Tab; strength: 200mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01997629 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14016
Interchangeable products
Co Etidronate · DIN 02248686 · $0.3569
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01997629
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 7, 2010 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (M05B, M05BA): coverage varies; not interchangeable

  • Alendronate (Fosamax): general benefit, not a benefit
  • Risedronate (Actonel DR): general benefit, not a benefit
  • Clodronate (Ostac): limited Use 280, 358, 359, not a benefit
  • Zoledronic acid (Aclasta): limited Use 319, 436, 523, not a benefit
  • Pamidronate (Aredia): not a benefit
  • Alendronate + cholecalciferol (Fosavance): general benefit

1 more in the class list below

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

RISEDRONATE SODIUM

· 23 products · General benefit (20), Listed, not a benefit (3) · strengths: 35mg, 5mg, 30mg, 150mg · DR Tab, Tab

CLODRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 280, 358, 359 (1) · strengths: 400mg · Cap

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (9), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

PAMIDRONATE DISODIUM

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Other review policies

For Didronel: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026